Royalty Pharma CFO reports 34,791-share insider sale
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026.
Rhea-AI Filing Summary
Royalty Pharma plc executive vice president and CFO Terrance P. Coyne reported indirect open-market sales of a total of 34,791 Class A ordinary shares of Royalty Pharma plc on March 2, 2026. The sales were made by entities TPC RP 2021, LLC and TPC RP EPA1 LLC at weighted average prices around $46.67 and $47.01 per share, in multiple transactions within disclosed price ranges. All reported transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on August 8, 2025.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 34,791 shares
Net Sell
8 txns
Insider
Coyne Terrance P.
Role
EVP & CFO
Sold
34,791 shs ($1.63M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Class A Ordinary Shares | 22,487 | $46.6717 | $1.05M |
| Sale | Class A Ordinary Shares | 10,429 | $47.0145 | $490K |
| Sale | Class A Ordinary Shares | 1,292 | $46.6747 | $60K |
| Sale | Class A Ordinary Shares | 583 | $47.0143 | $27K |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
| holding | Class A Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Class A Ordinary Shares — 98,748 shares (Indirect, By TPC RP 2021, LLC);
Class A Ordinary Shares — 45,761 shares (Indirect, TPC RP EPA1 LLC);
Class A Ordinary Shares — 24,170 shares (Indirect, By Spouse's IRA);
Class A Ordinary Shares — 23,270 shares (Indirect, By IRA);
Class A Ordinary Shares — 1,500 shares (Direct);
Class A Ordinary Shares — 1,450 shares (Indirect, By Spouse)
Footnotes (3)
- F1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.
- F2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.93 to $46.92 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $46.94 to $47.16 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Royalty Pharma (RPRX) disclose for Terrance P. Coyne?
Royalty Pharma disclosed that EVP and CFO Terrance P. Coyne reported indirect open-market sales of 34,791 Class A ordinary shares on March 2, 2026. The trades were executed through affiliated entities TPC RP 2021, LLC and TPC RP EPA1 LLC, not in his personal name.
Were the Royalty Pharma (RPRX) insider sales by Terrance P. Coyne pre-planned?
Yes. All reported transactions were effected under a Rule 10b5-1 trading plan adopted by Terrance P. Coyne on August 8, 2025. Such plans allow insiders to schedule trades in advance, helping separate routine portfolio management from opportunistic trading concerns.
What price ranges applied to the Royalty Pharma (RPRX) insider sales?
Footnotes explain that some sales occurred in multiple trades at prices ranging from $45.93 to $46.92 per share, and others between $46.94 and $47.16 per share. Reported prices are weighted averages, and detailed breakdowns are available upon written request to relevant parties.
What ongoing Royalty Pharma (RPRX) holdings are reported after these transactions?
Post-transaction figures show continuing indirect positions, including 98,748 and 45,761 Class A ordinary shares held via TPC RP 2021, LLC and TPC RP EPA1 LLC, plus additional indirect holdings through IRAs and a spouse, and a direct holding of 1,500 shares as of March 2, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
